Navigation Links
Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting
Date:6/4/2011

eatment for HER2-negative breast cancer, tumors with higher Oncotype DX Recurrence Scores at baseline were more likely to achieve a pathologic complete response.  The study, "Ixabepilone and cyclophosphamide as neoadjuvant therapy in HER2-negative breast cancer with exploratory Oncotype DX assessments: A Sarah Cannon Research Institute phase II trial" (Abstract #1066) will be presented on Monday, June 6.

Breast Cancer Recurrence Score Cannot Be Predicted by Traditional Clinicopathologic Measures

  • An analysis of 2,097 patients from Clalit Health Services and 484 patients from Maccabi Health Services in Tel Aviv, Israel who received the Oncotype DX breast cancer tests between January 2008 and June 2010 concluded that the RS result cannot be predicted by traditional clinicopathologic measures, such as patient age, tumor grade, and tumor size.  The study, "Evaluation of recurrence score and traditional clinicopathologic assessments in a large ER-positive, lymph node-negative patient cohort" (Abstract #632) will be presented on Monday, June 6.

Additional Breast Cancer Studies Expand Understanding of Tumor Biology

  • Based on published data comparing the relative efficacy of aromatase inhibitors and tamoxifen in reducing the risk of distant recurrence, researchers concluded that an individual patient's Recurrence Score and Recurrence Score-Clinical-Pathologic (RSPC) distant recurrence risk assessment can be used to determine distant recurrence risk for early-stage breast cancer patients receiving treatment with an aromatase inhibitor.  The study, "Using the 21-gene Recurrence Score (RS) and the recently developed Recurrence Score-Pathology-Clinical (RSPC) to assess recurrence risk in patients with node-negative, ER-positive early-stage breast cancer receiving aromatase inhibitor treatment alone
    '/>"/>

SOURCE Genomic Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Everist Genomics Announces New Data on OncoDefender™- CRC Test for Predicting Recurrence Risk for Stage I and II Colorectal Cancer Patients
2. Genomic Health to Present at Two Upcoming Investor Conferences
3. Signal Genetics Announces Commercialization Partnership with NeoGenomics Laboratories for Multiple Myeloma Gene Expression Test
4. Transgenomic, Inc. Acquires Exclusive Worldwide License to Predictive Markers for Cancer Drug Response
5. Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
6. Transgenomic Reports First Quarter Financial Results
7. Reminder: Transgenomic to Hold First Quarter Financial Results Conference Call Today
8. GT Life Sciences Broadens Intellectual Property Portfolio with Issuance of U.S. Patent on Core Computational Systems and Methods for Genomic-based Metabolic Modeling
9. CrystalGenomics Completes Phase I MAD Study of its Novel Antibiotic Candidate CG400549, and Prepares for Phase II Clinical Study
10. Rosetta Genomics Announces Issuance of Additional U.S. Patent
11. Transgenomic, Inc. Presents Its Latest Technology at the BIT Life Sciences World DNA and Genome Day Conference, Dalian, China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Weiss LLP is reporting that on July 13, 2015, the ... Bard, the manufacturer of Inferior vena cava (IVC) filters ... agency found at two of Bard,s facilities. Bard was previously ... during Inspectional Observations that occurred on November 18, 2014, through ... , location and on October 6, 2014, through November 25, ...
(Date:7/31/2015)... , July 31, 2015  Boston Children,s ... benefiting from 3D printing of their anatomy before ... life-threatening cerebrovascular malformations (abnormalities in the brain,s blood ... Reporting online today in the Journal of ... of 3D printing and synthetic resins to create ...
(Date:7/31/2015)... Scientific, Inc. (Nasdaq: SMLR ), a company that ... physician groups, today reported financial results for the second ... the second quarter of 2015, Semler reported continued progress ... over quarter revenue growth of 8%, and quarter over ... of 18%," said Doug Murphy-Chutorian, M.D., chief executive officer ...
Breaking Medicine Technology:Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 33D Printing Helps Doctors Rehearse Complex Brain Procedures 23D Printing Helps Doctors Rehearse Complex Brain Procedures 33D Printing Helps Doctors Rehearse Complex Brain Procedures 4Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6
... Southern California-based philanthropy Free Wheelchair Mission has ... International,s annual giving catalog. Called "Relief in ... humanitarian outreach operations, supporting causes including hunger alleviation, ... The two international nonprofits have collaborated since 2005, ...
... , BAD HOMBURG, Germany and LACHEN, Switzerland, Oct. ... signed a License, Development and Supply Agreement regarding ... develop a HESylated recombinant protein. , Under the ... Technology to Octapharma. This technology platform is based ...
Cached Medicine Technology:OC-Based Charity Teams with International Relief Organization in Holiday Fundraising Drive 2Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein 2Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein 3
(Date:8/1/2015)... ... , ... On March 19, 2015 Phil Valentine – the Executive Director of Connecticut Community for ... by stepping off Springer Mountain and heading north. Since that day, Phil has hiked over ... was greeted by friends and family. He visited CCAR and left an inspirational message ...
(Date:7/31/2015)... ... August 01, 2015 , ... Super Bowl 50 will emanate from Levi’s Stadium in ... each year is the Super Bowl. In the two weeks that separate the conference championships ... venue. The 2016 Super Bowl game will mark the 50th time it has been held ...
(Date:7/31/2015)... ... July 31, 2015 , ... The 2nd annual Ride to Fight On ... on October 3, 2015. The Ride to Fight On is a cycling fundraiser that ... Healthcare, The West Clinic and The University of Tennessee Health Science Center. A health ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Coco Libre announced ... judges, media, and VIPs at the 2015 Vans US Open of Surfing, July 25 ... that can claim “no added sugar” on the market, is a natural choice given ...
(Date:7/31/2015)... ... July 31, 2015 , ... Well-known for its unique ... wedding cakes with custom designs, making life just a little bit sweeter ... wedding cakes for each customer who orders one. , The bakery provides a full ...
Breaking Medicine News(10 mins):Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2
... created an uptick in his business as more people find themselves either ... back. , ... Concord, CA (PRWEB) April 3, 2009 -- As economies ... play out for the young but booming medical tourism industry . ...
... As news emerged that Gov. Kathleen Sebelius, nomination ... postponed until the end of April, American Life ... Pat Roberts to reject the nomination.(Logo: ... Courtesy" -- the longstanding Senate tradition only confirming ...
... completion may boost patient compliance, outcomes, researchers say , , ... antibiotic called moxifloxacin in combination with other drugs could ... takes to cure patients with drug-treatable tuberculosis, according to ... result in patients failing to complete their drug therapy, ...
... Event highlights accomplishments of three highly recruited adapted sports ... rehabilitation and resource center Courage Center has had a ... in adapted sports such as wheelchair basketball and rugby. ... high school seniors will sign college letters of intent ...
... the release of the first long-range plan for tackling ... Americans each year. , Opportunities and Challenges in Digestive ... Diseases describes the impact of diseases ranging from foodborne ... priorities for research over the next 10 years. The ...
... Healthcare Holdings, Inc. announced today that it has agreed ... County Physicians Investment Network, LLC, which is owned primarily ... shareholders, and certain related parties of OC-PIN. The ... in May, 2007 against two of its former directors ...
Cached Medicine News:Health News:Economic Turmoil Creates Boom for Medical Tourism 2Health News:Economic Turmoil Creates Boom for Medical Tourism 3Health News:Economic Turmoil Creates Boom for Medical Tourism 4Health News:A.L.L. Calls on KS Senators to Stop Sebelius as Confirmation Postponed 2Health News:New Antibiotic Could Shorten TB Treatment 2Health News:Courage Center Hosts College Scholarship Signing Ceremony Thursday, April 9, 2009 2Health News:NIH releases the first research plan to reduce the burden of digestive diseases 2Health News:NIH releases the first research plan to reduce the burden of digestive diseases 3Health News:IHHI Settles Litigation With OC-PIN 2
For the qualitative determination of magnesium in serum....
Intended for the quantitative determination of magnesium in serum or plasma. Reaction: Endpoint. Wavelength: 520 nm. Linearity: 6.0 mg/dL (2.5 mmol/L)....
For the quantitative determination of Magnesium in serum. Linearity: 4.0 mEq/L. Working Reagent prepared by simple 1:10 dilution....
For the quantitative determination of total glucose in serum....
Medicine Products: